ADCT stock news
This page provides real-time market news, earnings updates, and company announcements related to ADC Therapeutics SA (ADCT).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-04 09:21 EST
ICP Sees 30% Price Jump in Late October 2025: Institutional Interest and Web3 Goals Ignite Fresh Bullish Momentum
Bitget-RWA2025-11-07 17:22:05
Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Finviz2026-02-12 09:06:42
Kyntra Bio to Participate in Upcoming Investor Conferences
Finviz2026-02-17 21:09:42
Crescent Biopharma Announces First Patient Dosed in ASCEND Phase 1/2 Clinical Trial of CR-001 for the Treatment of Advanced Solid Tumors
Finviz2026-02-18 12:33:42
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
Finviz2026-02-18 14:09:35
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Finviz2026-02-20 13:33:46
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA.
老虎证券2026-02-23 12:27:32
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027.
老虎证券2026-02-23 12:27:32
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Finviz2026-02-23 13:34:18
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
Finviz2026-02-23 13:54:10
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
Finviz2026-02-23 22:15:05
AVGO Expands Connectivity Portfolio to Tap 6G: What's Ahead?
Finviz2026-02-24 16:36:38
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Finviz2026-02-24 21:03:47
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Finviz2026-02-26 12:33:48
BMY's Stock Slumps 0.33% Despite Strong Clinical Data, Trading Volume Ranks 201st
101 finance2026-02-26 23:24:44
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-02-27 13:03:11
Realty Income Stock: A Buy, Hold or Sell Opportunity Post Q4 Earnings?
Finviz2026-02-27 19:27:39
Biohaven Ltd. (BHVN): A Bull Case Theory
Finviz2026-02-28 15:09:06
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
Finviz2026-03-02 12:33:45
BMY Shares Dip 0.05% on Mixed Signals $1.1B Volume 117th NYSE Rank Highlight Dividend-Earnings Divide
101 finance2026-03-02 23:09:46
Immunome’s Q4: Results Fall Short, But 2026 Expectations Are Key
101 finance2026-03-04 01:45:50
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
Finviz2026-03-04 13:03:46
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
Finviz2026-02-18 14:09:35
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval
Finviz2026-02-20 13:33:46
Healthcare Royalty Partners granted warrants to purchase approximately 9.8 million ordinary shares to ADC Therapeutics SA.
老虎证券2026-02-23 12:27:32
ADC Therapeutics SA (ADCT) recently released its performance outlook, expecting the company to enter a substantial growth phase starting in 2027.
老虎证券2026-02-23 12:27:32
Sutro Biopharma Announces Participation at the 16th World ADC London Summit
Finviz2026-02-23 13:34:18
Akari Therapeutics Appoints Globally Recognized Expert in RNA Biology and Cancer Research, Olga Anczukow, Ph.D., to its Scientific Advisory Board
Finviz2026-02-23 13:54:10
Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026
Finviz2026-02-23 22:15:05
AVGO Expands Connectivity Portfolio to Tap 6G: What's Ahead?
Finviz2026-02-24 16:36:38
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Finviz2026-02-24 21:03:47
Crescent Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Finviz2026-02-26 12:33:48
BMY's Stock Slumps 0.33% Despite Strong Clinical Data, Trading Volume Ranks 201st
101 finance2026-02-26 23:24:44
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-02-27 13:03:11
Realty Income Stock: A Buy, Hold or Sell Opportunity Post Q4 Earnings?
Finviz2026-02-27 19:27:39
Biohaven Ltd. (BHVN): A Bull Case Theory
Finviz2026-02-28 15:09:06
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
Finviz2026-03-02 12:33:45
BMY Shares Dip 0.05% on Mixed Signals $1.1B Volume 117th NYSE Rank Highlight Dividend-Earnings Divide
101 finance2026-03-02 23:09:46
Immunome’s Q4: Results Fall Short, But 2026 Expectations Are Key
101 finance2026-03-04 01:45:50
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026
Finviz2026-03-04 13:03:46
ADCT stock chart
ADCT stock detailsADCT stock price change
On the last trading day, ADCT stock closed at 4.03 USD, with a price change of -3.59% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more